CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH’s website.
CADTH has three new consultations ... Read More
08
Aug2019
17
Jun2019
New “PROVISIONAL ALGORITHMS” at the Centre of Changes to Cancer Therapy Reviews
Effective July 1, 2019, process and operational changes will be made to integrate the functions of the Cancer Drug Implementation Advisory Committee (CDIAC) to CADTH and its pCODR process. Solicitation of stakeholder feedback began in March of this year. The integration of CDIAC into the pCODR process is intended to further enhance transparency of cancer ... Read More
24
May2019
CADTH’s Pharmaceutical Review Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH’s website.
There are seven important announcements from CADTH:
... Read More
05
Mar2019
On February 28, 2019, Health Canada and CADTH, with INESSS participating as an observer, announced a new joint Early Parallel Scientific Advice collaboration. The initiative seeks to provide more timely access to medicines for Canadians. Through this initiative, drug sponsors will obtain advice in parallel from Health Canada and ... Read More
22
Feb2019
CADTH is launching a new Patient and Community Advisory Committee
After talks with patient groups this past fall, CADTH is creating a 12-person advisory committee to discuss the experiences of patients and family caregivers in Canada. They invite nominations for those with extensive experience as a patient or family caregiver in ... Read More
12
Apr2018
A new Patient Evidence Submission Tip Sheet offers guidance to patient groups on the types of information that should be included in a CADTH pan-Canadian Oncology Drug Review (pCODR) patient group input submission, as well as how the evidence can best be presented.
The new Tip Sheet, along with the ... Read More
13
Sep2016
CADTH is inviting stakeholder comments on proposed changes to the patient input template for the CADTH Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR). Patient input is used by CADTH review teams and by the expert committees of the CDR and pCODR programs: the CADTH Canadian ... Read More
26
May2016
Effective immediately, CADTH will be formally engaging with the pan-Canadian Pharmaceutical Alliance (pCPA) and will be including the pCPA office in the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) processes. This will provide an opportunity for the pCPA office to receive relevant information on drugs reviewed ... Read More
30
Mar2016
Recommendation Framework for CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) Programs
In collaboration with the participating jurisdictions and with input from stakeholders, CADTH has established a single recommendation framework to support the drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert ... Read More
24
Mar2016
Effective April 1, 2016, all drug products reviewed by the Common Drug Review (CDR) and the pan-Canadian Oncology Drug Review (pCODR) will no longer require a routine review by the Committee to Evaluate Drugs (CED), the Ontario Ministry of Health and Long-Term Care’s expert drug advisory committee. This change also ... Read More